{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:04:44Z","timestamp":1793639084815,"version":"4.5.1"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Breast cancer is the most common malignancy in women. Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+\/HER2-) breast cancer patients rely on endocrine therapy as their fundamental systemic treatment strategy. This study aims to comprehensively evaluate the patterns of neurotoxicity and psychotoxicity across different classes of endocrine therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Pharmacovigilance data related to endocrine therapy for breast cancer from the FDA Adverse Event Reporting System (FAERS) and WHO VigiAccess database were utilized. The disproportionality algorithms, including reporting odds ratio and information component, were employed in FAERS to investigate the patterns, influencing factors, and outcomes of neurological and psychiatric event burdens in selective estrogen receptor modulators (SERMs), selective estrogen receptor degraders (SERDs), and aromatase inhibitors (AIs). Sensitivity analysis was conducted using VigiAccess as a supplementary data source.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 64,731 FAERS and 116,605 VigiAccess safety reports on endocrine therapies were analyzed. Neurotoxic and psychiatric events accounted for approximately 20% and 10% of these reports, respectively. The most common neurologic adverse events were headache, dizziness, and sensory impairment, while insomnia, depression, and anxiety were the most frequent psychiatric events. The disproportionality analysis indicated that SERMs showed several strong neurovascular safety signals, such as cerebral venous thrombosis and dural arteriovenous fistula. Both SERMs and AIs showed positive signals for depression, whereas SERDs did not. All therapies exhibited an \u201cearly failure\u201d pattern in time-to-onset analyses (\u03b2 = 0.54\u20130.66).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study conducted a comprehensive pharmacovigilance assessment of neurotoxicity and psychiatric events in endocrine therapy for breast cancer. The findings indicated heterogeneous patterns of neuropsychiatric safety signals and reporting burdens across drug classes, offering new insights relevant to clinical monitoring practices.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1731849","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T06:56:29Z","timestamp":1772693789000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Profiles of neuropsychiatric toxicity associated with different endocrine therapies for breast cancer: a global pharmacovigilance study based on FAERS and VigiAccess"],"prefix":"10.3389","volume":"17","author":[{"given":"Guoqiang","family":"Li","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Peking University Shenzhen Hospital, Hong Kong University of Science and Technology Medical Center","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqi","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Peking University Shenzhen Hospital, Hong Kong University of Science and Technology Medical Center","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Peking University Shenzhen Hospital, Hong Kong University of Science and Technology Medical Center","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Peking University Shenzhen Hospital, Hong Kong University of Science and Technology Medical Center","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoliang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Peking University Shenzhen Hospital, Hong Kong University of Science and Technology Medical Center","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Peking University Shenzhen Hospital, Hong Kong University of Science and Technology Medical Center","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajie","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Peking University Shenzhen Hospital, Hong Kong University of Science and Technology Medical Center","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.yhbeh.2015.06.010","article-title":"Estrogen receptors in the central nervous system and their implication for dopamine-dependent cognition in females","volume":"74","author":"Almey","year":"2015","journal-title":"Horm. Behav."},{"key":"B2","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.neulet.2016.04.023","article-title":"Estrogen receptor \u03b1 and G-protein coupled estrogen receptor 1 are localized to GABAergic neurons in the dorsal striatum","volume":"622","author":"Almey","year":"2016","journal-title":"Neurosci. Lett."},{"key":"B3","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1590\/0004-282X20140221","article-title":"Tamoxifen antagonizes the effects of ovarian hormones to induce anxiety and depressionlike behavior in rats","volume":"73","author":"Azizi-Malekabadi","year":"2015","journal-title":"Arq. Neuropsiquiatr."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1016\/j.clinthera.2018.07.012","article-title":"Pharmacovigilance: an overview","volume":"40","author":"Beninger","year":"2018","journal-title":"Clin. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1182\/bloodadvances.2021006623","article-title":"Differential impact of tamoxifen and aromatase inhibitors on thrombin generation: the prospective HEMOBREAST cohort","volume":"6","author":"Blondon","year":"2022","journal-title":"Blood Adv."},{"key":"B6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1038\/npp.2017.95","article-title":"Direct and systemic administration of a CNS-Permeant tamoxifen analog reduces amphetamine-induced dopamine release and reinforcing effects","volume":"42","author":"Carpenter","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1212\/WNL.0000000000001776","article-title":"Estrogen actions in the nervous system","volume":"85","author":"Cersosimo","year":"2015","journal-title":"Neurology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/s0091-3057(01)00656-6","article-title":"Tamoxifen and toremifene cause impairment of learning and memory function in mice","volume":"71","author":"Chen","year":"2002","journal-title":"Pharmacol. Biochem. Behav."},{"key":"B10","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.yhbeh.2014.07.005","article-title":"Decision-making impairments in breast cancer patients treated with tamoxifen","volume":"66","author":"Chen","year":"2014","journal-title":"Horm. Behav."},{"key":"B11","doi-asserted-by":"publisher","first-page":"566","DOI":"10.3390\/jcm9020566","article-title":"Aromatase inhibitors and risk of arthritis and carpal tunnel syndrome among taiwanese women with breast cancer: a nationwide claims data analysis","volume":"9","author":"Chien","year":"2020","journal-title":"J. Clin. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"445E","DOI":"10.1097\/PRS.0000000000008835","article-title":"Aromatase inhibitor-induced carpal tunnel syndrome and stenosing tenosynovitis: a systematic review","volume":"149","author":"Chung","year":"2022","journal-title":"Plast. Reconstr. Surg."},{"key":"B13","doi-asserted-by":"publisher","first-page":"115600","DOI":"10.1016\/j.taap.2021.115600","article-title":"A new clinically-relevant rat model of letrozole-induced chronic nociceptive disorders","volume":"425","author":"Collin","year":"2021","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.3390\/cancers14205132","article-title":"Anti-Hormonal therapy in breast cancer and its effect on the blood-brain barrier","volume":"14","author":"Curtaz","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1387251","DOI":"10.3389\/fonc.2024.1387251","article-title":"Cancer related cognitive impairment: a downside of cancer treatment","volume":"14","author":"Demos-Davies","year":"2024","journal-title":"Front. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40478-015-0255-6","article-title":"Tamoxifen induces cellular stress in the nervous system by inhibiting cholesterol synthesis","volume":"3","author":"Denk","year":"2015","journal-title":"Acta Neuropathol. Commun."},{"key":"B17","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40360-025-00887-2","article-title":"Post-marketing safety of elacestrant in breast cancer: a pharmacovigilance investigation using the FDA adverse event reporting system","volume":"26","author":"Fan","year":"2025","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of A disproportionality analysis for DrUg safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1007\/s40264-025-01573-2","article-title":"Strategies and challenges in coding ambiguous information using MedDRA\u00ae: an exploration among Norwegian pharmacovigilance officers","volume":"48","author":"Garmann","year":"2025","journal-title":"Drug Saf."},{"key":"B20","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.schres.2015.04.029","article-title":"Comparing the effects of 17\u03b2-oestradiol and the selective oestrogen receptor modulators, raloxifene and tamoxifen, on prepulse inhibition in female rats","volume":"168","author":"Gogos","year":"2015","journal-title":"Schizophr. Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3390\/cancers14040920","article-title":"Effects of endocrine therapy on cognitive function in patients with breast cancer: a comprehensive review","volume":"14","author":"Haggstrom","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: a systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf."},{"key":"B23","doi-asserted-by":"publisher","first-page":"480","DOI":"10.3322\/caac.21777","article-title":"Systemic therapy for hormone receptor\u2010positive\/human epidermal growth factor receptor 2\u2010negative early stage and metastatic breast cancer","volume":"73","author":"Huppert","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"B24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ijscr.2014.11.068","article-title":"Cerebral venous thrombosis in a breast cancer patient taking tamoxifen: report of a case","volume":"6","author":"Kim","year":"2015","journal-title":"Int. J. Surg. Case Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ajo.2025.05.007","article-title":"Association of glucagon-like Peptide-1 receptor agonists with optic nerve and retinal adverse events: a population-based observational study across 180 countries","volume":"277","author":"Lakhani","year":"2025","journal-title":"Am. J. Ophthalmol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"pkad022","DOI":"10.1093\/jncics\/pkad022","article-title":"Effects of tamoxifen and exemestane on cognitive function in postmenopausal patients with breast cancer","volume":"7","author":"Lee Meeuw Kjoe","year":"2023","journal-title":"JNCI Cancer Spectr."},{"key":"B27","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/14740338.2024.2416917","article-title":"Safety study on adverse events of zanubrutinib based on WHO-VigiAccess and FAERS databases","volume":"25","author":"Liang","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"B28","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1159\/000546678","article-title":"Evaluation of safety of elacestrant in patients with breast cancer: insights from food and drug administration adverse event reporting system database analysis","volume":"20","author":"Lv","year":"2025","journal-title":"Breast Care"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e0126413","DOI":"10.1371\/journal.pone.0126413","article-title":"Bias in spontaneous reporting of adverse drug reactions in Japan","volume":"10","author":"Matsuda","year":"2015","journal-title":"PLoS One"},{"key":"B30","doi-asserted-by":"publisher","first-page":"k3845","DOI":"10.1136\/bmj.k3845","article-title":"Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review","volume":"363","author":"Matthews","year":"2018","journal-title":"BMJ (Online)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/jnc.13955","article-title":"Tamoxifen and its active metabolites inhibit dopamine transporter function independently of the estrogen receptors","volume":"141","author":"Mikelman","year":"2017","journal-title":"J. Neurochem."},{"key":"B32","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1186\/s12885-025-14277-8","article-title":"Effect of breast cancer surgery on levels of depression and anxiety: a systematic review and meta-analysis","volume":"25","author":"Movahed","year":"2025","journal-title":"BMC Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"100869","DOI":"10.1016\/j.yfrne.2020.100869","article-title":"Neuropsychiatric effects of tamoxifen: challenges and opportunities","volume":"59","author":"Novick","year":"2020","journal-title":"Front. Neuroendocrinol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3390\/cancers11050687","article-title":"Pretreatment cancer-related cognitive impairment-mechanisms and outlook","volume":"11","author":"Olson","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.yhbeh.2015.09.004","article-title":"Memory enhancement by tamoxifen on amyloidosis mouse model","volume":"79","author":"Pandey","year":"2016","journal-title":"Horm. Behav."},{"key":"B36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41523-023-00523-4","article-title":"An emerging generation of endocrine therapies in breast cancer: a clinical perspective","volume":"9","author":"Patel","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1158\/1078-0432.CCR-24-0195","article-title":"Metabolomic prediction of breast cancer treatment\u2013induced neurologic and metabolic toxicities","volume":"30","author":"Piffoux","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s10549-019-05271-3","article-title":"Global prevalence of depression among breast cancer patients: a systematic review and meta-analysis","volume":"176","author":"Pilevarzadeh","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"B39","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s13311-019-00766-9","article-title":"The role of estrogen in brain and cognitive aging","volume":"16","author":"Russell","year":"2019","journal-title":"Neurotherapeutics"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms22020972","article-title":"The complex interplay between endocannabinoid system and the estrogen system in central nervous system and periphery","volume":"22","author":"Santoro","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.3390\/cancers16162827","article-title":"Mental health challenges in cancer patients: a cross-sectional analysis of depression and anxiety","volume":"16","author":"Shalata","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1007\/s00198-023-06877-6","article-title":"A real-world pharmacovigilance study of abaloparatide based on the FDA adverse event reporting system (FAERS)","volume":"34","author":"Shi","year":"2023","journal-title":"Osteoporos. Int."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.22034\/APJCP.2018.19.6.1661","article-title":"Assessment of depression and anxiety in breast cancer patients: prevalence and associated factors","volume":"19","author":"Tsaras","year":"2018","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"B44","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.yhbeh.2018.06.012","article-title":"Is the membrane estrogen receptor, GPER1, a promiscuous receptor that modulates nuclear estrogen receptor-mediated functions in the brain?","volume":"104","author":"Vajaria","year":"2018","journal-title":"Horm. Behav."},{"key":"B45","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA - J. Am. Med. Assoc."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1186\/s12885-025-14667-y","article-title":"The influence of cancer treatments on long-term psychological outcomes and quality of life in breast cancer patients","volume":"25","author":"Yang","year":"2025","journal-title":"BMC Cancer"},{"key":"B47","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jad.2023.11.076","article-title":"Mining and analysis of adverse event signals of cariprazine based on the real-world data of FAERS database","volume":"347","author":"Zhu","year":"2024","journal-title":"J. Affect Disord."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1731849\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T06:56:31Z","timestamp":1772693791000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1731849\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":47,"alternative-id":["10.3389\/fphar.2026.1731849"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1731849","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]},"article-number":"1731849"}}